These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

491 related articles for article (PubMed ID: 25011693)

  • 1. Angiotensin blockade and progressive loss of kidney function in hemodialysis patients: a randomized controlled trial.
    Kjaergaard KD; Peters CD; Jespersen B; Tietze IN; Madsen JK; Pedersen BB; Novosel MK; Laursen KS; Bibby BM; Strandhave C; Jensen JD
    Am J Kidney Dis; 2014 Dec; 64(6):892-901. PubMed ID: 25011693
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Renal and cardiovascular effects of irbesartan in dialysis patients--a randomized controlled trial protocol (SAFIR study).
    Peters CD; Kjærgaard KD; Jespersen B; Christensen KL; Jensen JD
    Dan Med J; 2013 Apr; 60(4):A4602. PubMed ID: 23651713
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Effects of Sacubitril/Valsartan Versus Irbesartan in Patients With Chronic Kidney Disease.
    Haynes R; Judge PK; Staplin N; Herrington WG; Storey BC; Bethel A; Bowman L; Brunskill N; Cockwell P; Hill M; Kalra PA; McMurray JJV; Taal M; Wheeler DC; Landray MJ; Baigent C
    Circulation; 2018 Oct; 138(15):1505-1514. PubMed ID: 30002098
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Short and Long-Term Effects of the Angiotensin II Receptor Blocker Irbesartan on Intradialytic Central Hemodynamics: A Randomized Double-Blind Placebo-Controlled One-Year Intervention Trial (the SAFIR Study).
    Peters CD; Kjaergaard KD; Jensen JD; Christensen KL; Strandhave C; Tietze IN; Novosel MK; Bibby BM; Jespersen B
    PLoS One; 2015; 10(6):e0126882. PubMed ID: 26030651
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Long-term effects of angiotensin II blockade with irbesartan on inflammatory markers in hemodialysis patients: A randomized double blind placebo controlled trial (SAFIR study).
    Peters CD; Kjaergaard KD; Nielsen CH; Christensen KL; Bibby BM; Jensen JD; Jespersen B
    Hemodial Int; 2017 Jan; 21(1):47-62. PubMed ID: 27346437
    [TBL] [Abstract][Full Text] [Related]  

  • 6. No significant effect of angiotensin II receptor blockade on intermediate cardiovascular end points in hemodialysis patients.
    Peters CD; Kjaergaard KD; Jensen JD; Christensen KL; Strandhave C; Tietze IN; Novosel MK; Bibby BM; Jensen LT; Sloth E; Jespersen B
    Kidney Int; 2014 Sep; 86(3):625-37. PubMed ID: 24670413
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Estimated GFR decline as a surrogate end point for kidney failure: a post hoc analysis from the Reduction of End Points in Non-Insulin-Dependent Diabetes With the Angiotensin II Antagonist Losartan (RENAAL) study and Irbesartan Diabetic Nephropathy Trial (IDNT).
    Lambers Heerspink HJ; Weldegiorgis M; Inker LA; Gansevoort R; Parving HH; Dwyer JP; Mondal H; Coresh J; Greene T; Levey AS; de Zeeuw D
    Am J Kidney Dis; 2014 Feb; 63(2):244-50. PubMed ID: 24210590
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Effect of dual blockade of the renin-angiotensin system on the progression of type 2 diabetic nephropathy: a randomized trial.
    Fernandez Juarez G; Luño J; Barrio V; de Vinuesa SG; Praga M; Goicoechea M; Cachofeiro V; Nieto J; Fernández Vega F; Tato A; Gutierrez E;
    Am J Kidney Dis; 2013 Feb; 61(2):211-8. PubMed ID: 22939518
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Independent and additive impact of blood pressure control and angiotensin II receptor blockade on renal outcomes in the irbesartan diabetic nephropathy trial: clinical implications and limitations.
    Pohl MA; Blumenthal S; Cordonnier DJ; De Alvaro F; Deferrari G; Eisner G; Esmatjes E; Gilbert RE; Hunsicker LG; de Faria JB; Mangili R; Moore J; Reisin E; Ritz E; Schernthaner G; Spitalewitz S; Tindall H; Rodby RA; Lewis EJ
    J Am Soc Nephrol; 2005 Oct; 16(10):3027-37. PubMed ID: 16120823
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Effect of pentoxifylline on GFR decline in CKD: a pilot, double-blind, randomized, placebo-controlled trial.
    Perkins RM; Aboudara MC; Uy AL; Olson SW; Cushner HM; Yuan CM
    Am J Kidney Dis; 2009 Apr; 53(4):606-16. PubMed ID: 19216016
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Worsening renal function and outcome in heart failure patients with preserved ejection fraction and the impact of angiotensin receptor blocker treatment.
    Damman K; Perez AC; Anand IS; Komajda M; McKelvie RS; Zile MR; Massie B; Carson PE; McMurray JJ
    J Am Coll Cardiol; 2014 Sep; 64(11):1106-13. PubMed ID: 25212644
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Quality of life development during initial hemodialysis therapy and association with loss of residual renal function.
    Poulsen CG; Kjaergaard KD; Peters CD; Jespersen B; Jensen JD
    Hemodial Int; 2017 Jul; 21(3):409-421. PubMed ID: 27804233
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Irbesartan reduces creatinine clearance in type 1 diabetic children with renal hyperfunction: a randomized, double-blind, placebo-controlled trial.
    Salcedo-Alejos M; Banda-Espinoza F; Rodríguez-Morán M; Guerrero-Romero F
    Nephrol Dial Transplant; 2005 Oct; 20(10):2120-5. PubMed ID: 16091379
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Randomized multicentre pilot study of sacubitril/valsartan versus irbesartan in patients with chronic kidney disease: United Kingdom Heart and Renal Protection (HARP)- III-rationale, trial design and baseline data.
    UK HARP-III Collaborative Group
    Nephrol Dial Transplant; 2017 Dec; 32(12):2043-2051. PubMed ID: 27646835
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Treatment of diabetic nephropathy with angiotensin II receptor antagonist.
    Lewis EJ; Lewis JB
    Clin Exp Nephrol; 2003 Mar; 7(1):1-8. PubMed ID: 14586737
    [TBL] [Abstract][Full Text] [Related]  

  • 16. A randomized placebo controlled trial of early treatment of acute ischemic stroke with atorvastatin and irbesartan.
    Beer C; Blacker D; Bynevelt M; Hankey GJ; Puddey IB
    Int J Stroke; 2012 Feb; 7(2):104-11. PubMed ID: 22044557
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Is Chronic Dialysis the Right Hard Renal End Point To Evaluate Renoprotective Drug Effects?
    Weldegiorgis M; de Zeeuw D; Dwyer JP; Mol P; Heerspink HJL
    Clin J Am Soc Nephrol; 2017 Oct; 12(10):1595-1600. PubMed ID: 28923834
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Serum levels of the advanced glycation end products Nepsilon-carboxymethyllysine and pentosidine are not influenced by treatment with the angiotensin receptor II type 1 blocker irbesartan in patients with type 2 diabetic nephropathy and hypertension.
    Busch M; Franke S; Wolf G; Rohde RD; Stein G;
    Nephron Clin Pract; 2008; 108(4):c291-7. PubMed ID: 18434751
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Hong Kong study using valsartan in IgA nephropathy (HKVIN): a double-blind, randomized, placebo-controlled study.
    Li PK; Leung CB; Chow KM; Cheng YL; Fung SK; Mak SK; Tang AW; Wong TY; Yung CY; Yung JC; Yu AW; Szeto CC;
    Am J Kidney Dis; 2006 May; 47(5):751-60. PubMed ID: 16632013
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Renin-angiotensin system blockers and residual kidney function loss in patients initiating peritoneal dialysis: an observational cohort study.
    Shen JI; Saxena AB; Vangala S; Dhaliwal SK; Winkelmayer WC
    BMC Nephrol; 2017 Jun; 18(1):196. PubMed ID: 28623899
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 25.